$4.81
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America
Overview
52-week range
$2.78
$6.45
55% of range
Avg surprise (last 3)
+12.6%
Avg reaction (last 2)
+5.2%
100% positive
Latest IV / EM
250%
EM ±57.2% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.57 | $-0.60 | +5.0% | -42.5% | +1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.53 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.44 | $-0.46 | +4.3% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.40 | $-0.56 | +28.6% | — | +8.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.37 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.48 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.75 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.40 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.56 | -$0.44 | -27.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-48M | — | $-46M | $-41M | $-39M | — | $-37M | $-47M |
| Net income | $-45M | — | $-42M | $-37M | $-34M | — | $-31M | $-41M |
| EPS (diluted) | $-0.57 | — | $-0.53 | $-0.44 | $-0.40 | — | $-0.37 | $-0.48 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $79M | $96M | $77M | $88M | $119M | $65M | $98M | $243M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $263M | $311M | $336M | $386M | $434M | $462M | $487M | $506M |
| Total assets | $267M | $315M | $343M | $392M | $440M | $465M | $491M | $510M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | $27M | $27M | $29M | $26M | $32M | $34M |
| Total equity | $234M | $275M | $316M | $364M | $411M | $439M | $459M | $476M |